Suchergebnisse - "Nappi, Anna"

PubPharm (69)

61

AXL is an oncotarget in human colorectal cancer

enthalten in: Oncotarget | 2015

von Martinelli, E. | Martini, G. | Cardone, C. | +17

62

Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab

enthalten in: Recenti progressi in medicina | 2015

von De Divitiis, C. | Cassata, A. | Nasti, G. | +4

63

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2014

von Troiani, T. | Napolitano, S. | Vitagliano, D. | +7

64

Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

enthalten in: Clinical cancer research | 2014

von Troiani, T. | Napolitano, S. | Vitagliano, D. | +7

65

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2013

von Troiani, T. | Martinelli, E. | Napolitano, S. | +12

66

Increased TGF- as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFRMET Interaction and Activation of MET Signaling in Colon Cancer Cells

enthalten in: Clinical cancer research | 2013

von Troiani, T. | Martinelli, E. | Napolitano, S. | +12

67

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

enthalten in: International journal of cancer | 2013

von Martinelli, E. | Troiani, T. | D'Aiuto, E. | +15

68

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells

enthalten in: International journal of cancer | 2013

von Martinelli, E. | Troiani, T. | D'Aiuto, E. | +15

69

Targeted approach to metastatic colorectal cancer : what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

enthalten in: Therapeutic advances in medical oncology | 2013

von Troiani, T. | Martinelli, E. | Morgillo, F. | +4

[1]
« Vorheriger
1
2
3
4
5
6
7